CHRS Projected Dividend Yield
Coherus BioSciences Inc ( NASDAQ : CHRS )Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. Co. is focused on the research, development and commercialization of immunotherapies to treat cancer. Co.'s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. 21 YEAR PERFORMANCE RESULTS |
CHRS Dividend History Detail CHRS Dividend News CHRS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |